Boehringer Ingelheim

Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
Farxiga
diabetes
AstraZeneca
heart failure
Flag link:
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
Fierce Pharma
diabetes
AHA
heart failure
Eli Lilly
Boehringer Ingelheim
Jardiance
clinical trials
Flag link:
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Zacks.com
Eli Lilly
Boehringer Ingelheim
FDA
Jardiance
type 1 diabetes
Flag link:
Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
Lilly and Boehringer rejig diabetes alliance as Jardiance soars
Lilly and Boehringer rejig diabetes alliance as Jardiance soars
Pharmaforum
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
type 2 diabetes
Flag link:
Which big pharma firms are best at digital?
Which big pharma firms are best at digital?
Pharmaforum
digital pharma
Bayer
Pfizer
Boehringer Ingelheim
Flag link:
Boehringer's VC wing backs anti-cancer virus startup
Boehringer's VC wing backs anti-cancer virus startup
Fierce Biotech
Abalos Therapeutics
arenavirus
Boehringer Ingelheim
cancer
Flag link:
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
Endpoints
KRAS
cancer
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Fierce Pharma
Boehringer Ingelheim
Ofev
idiopathic pulmonary fibrosis
Flag link:
Boehringer Ingelheim signs retinal disease deal with Inflammasome
Boehringer Ingelheim signs retinal disease deal with Inflammasome
Pharmaceutical Business Review
Boehringer Ingelheim
Inflammasome Therapeutics
retinal disease
Flag link:
EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod
EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
kidney disease
JNJ
EASD
Flag link:
ICER dings Novo's new oral diabetes drug
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
Flag link:
Boehringer Ingelheim’s Ofev secures FDA approval for SSc-ILD
Boehringer Ingelheim’s Ofev secures FDA approval for SSc-ILD
Pharmaceutical Business Review
Ofev
SSc-ILD
Boehringer Ingelheim
FDA
Flag link:
After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team
After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team
Endpoints
Boehringer Ingelheim
R&D
Flag link:
Companies file suit in Canada challenging new rules to lower drug prices
Companies file suit in Canada challenging new rules to lower drug prices
Yahoo/Reuters
drug pricing
Canada
Janssen
Merck
Bayer
Servier
Boehringer Ingelheim
Flag link:
MD Anderson and Boehringer Ingelheim to Partner on Cancer, Found a Virtual R&D Center
MD Anderson and Boehringer Ingelheim to Partner on Cancer, Found a Virtual R&D Center
BioSpace
Boehringer Ingelheim
MD Anderson Cancer Center
cancer
R&D
Flag link:
Boehringer posts solid first half as business revamp beds in
Boehringer posts solid first half as business revamp beds in
PM Live
Boehringer Ingelheim
earnings
Spiriva
Jardiance
Flag link:
Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M
Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M
Fierce Biotech
Boehringer Ingelheim
Bridge Biotherapeutics
Ofeva
IPF
BBT-877
Flag link:
Boehringer buys up cancer vaccine player, eyes oncology combo strategy
Boehringer buys up cancer vaccine player, eyes oncology combo strategy
Fierce Biotech
Boehringer Ingelheim
M&A
Amal Therapeutics
Flag link:
Boehringer races to catch up in NASH through Yuhan deal
Boehringer races to catch up in NASH through Yuhan deal
BioCentury
Boehringer Ingelheim
NASH
Yuhan
Flag link:

Pages